O. B. Sutcliffe et al. / Tetrahedron 56 (2000) 10011±10021
10017
84.8 (CH), 108.9, 117.0, 131.2, 138.0, 163.6 (CvO ester)
and 165.1 (CvO ester); m/z M1 285 (16%), 254 (100) and
222 (28).
7.7%); nmax (Nujolw) 2925, 1726, 1698, 1462, 1377, 1306,
1206, 1154 and 109 cm21; dH (CDCl3) 2.34 (s, 3H, 5-CH3),
2.54 (s, 3H, N±CH3), 3.83 (s, 3H, ester CH3), 3.86 (s, 3H,
ester CH3), 4.00 (dd, 1H, J4, 7 Hz, imide a-H), 4.02 (dd,
1H, J4, 7 Hz, imide a-H), 5.44 (d, 1H, J4 Hz, sulfur
bridge-H), and 6.02 (d, 1H, J4 Hz, sulfur bridge-H); dC
(CDCl3) 10.9 (CH3), 24.5 (CH3), 50.8 (CH), 51.9 (CH3
ester), 52.1 (CH3 ester), 53.4 (CH), 55.9 (CH), 67.4 (CH),
107.8, 114.3, 132.2, 138.1, 162.8 (CvO ester), 164.9 (CvO
ester), 172.0 (CvO amide) and 174.0 (CvO amide); m/z
M1 364 (34%), 332 (18), 253 (100), 221 (37), 163 (31), 135
(20).
General procedure for generation and trapping of `non-
classical' thiazole (1)
Dimethyl 5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicar-
boxylate 2-oxide 5 (0.27 g, 1.0 mmol) and the appropriate
dipolarophile (1.2 mmol) in acetic anhydride (5 mL) were
heated to re¯ux for 4 h. The reaction mixture was cooled to
room temperature and the solvent removed in vacuo. The
resulting residue was triturated with methanol to give the
cycloadduct which was further puri®ed by ¯ash chroma-
tography and/or recrystallisation from the appropriate
solvent.
Dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-
2-ethyl-6-methyl-1H-pyrrolo[3,4-f]indolizine-7,8-dicar-
boxylate (8a, exo) and (8b, endo). Dimethyl 5-methyl-
1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate 2-oxide 5
(0.27 g, 1.0 mmol) and N-ethylmaleimide (0.15 g, 1.2
equiv., 1.2 mmol) gave after chromatography [ethyl acetate±
hexane (1:1)] and crystallisation from chloroform±ethanol
(exo-adduct) dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-
hexahydro-2-ethyl-6-methyl-1H-pyrrolo[3,4-f]indolizine-
7,8-dicarboxylate (0.17 g, 46%) as a colourless powder, mp
212±2138C. (Found: C, 54.0; H, 4.8; N, 7.4. C17H18N2SO6
requires C, 54.0; H, 4.8 and N, 7.4%); nmax (Nujolw) 2926,
1777, 1699, 1533, 1456, 1378, 1348, 1302, 1205, 1153,
1093, 911 and 783 cm21; dH (CDCl3) 1.18 (t, 3H, J7 Hz,
CH3CH2-N), 2.44 (s, 3H, 5-CH3), 3.29 (d, 1H, J7 Hz,
imide a-H), 3.32 (d, 1H, J7 Hz, imide a-H), 3.59 (q,
2H, J7 Hz, CH3CH2-N), 3.82 (s, 3H, ester CH3), 3.85 (s,
3H, ester CH3), 5.39 (s, 1H, sulfur bridge-H), and 5.93 (s,
1H, sulfur bridge-H); dC (CDCl3) 11.3 (CH3), 12.5 (CH3),
34.5 (CH2), 50.6 (CH), 51.6 (CH3 ester), 51.8 (CH3 ester),
52.0 (CH), 53.3 (CH), 67.1 (CH), 107.8, 114.3, 131.4, 140.4,
163.1 (CvO ester), 164.9 (CvO ester), 173.1 (CvO
amide) and 173.8 (CvO amide); m/z M1 378 (23%), 346
(15), 253 (100), 221 (35), 163 (21), 135 (19), and (endo-
adduct) dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexa-
hydro-2-ethyl-6-methyl-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (0.02 g, 6%) as a colourless powder, mp dec.
234±2358C. (Found: C, 53.9; H, 4.7; N, 7.4. C17H18N2SO6
requires C, 54.0; H, 4.8 and N, 7.4%); nmax (Nujolw) 2926,
1778, 1699, 1532, 1456, 1378, 1347, 1302, 1205, 1153,
1093, 910 and 783 cm21; dH (CDCl3) 0.77 (t, 3H, J7 Hz,
CH3CH2-N), 2.35 (s, 3H, 5-CH3), 3.16 (q, 2H, J7 Hz,
CH3CH2-N), 3.82 (s, 3H, ester CH3), 3.85 (s, 3H, ester
CH3), 4.01 (dd, 1H, J4, 7 Hz, imide a-H), 4.06 (d, 1H,
J4, 7 Hz, imide a-H), 5.44 (d, 1H, J4 Hz, sulfur bridge-
H), and 6.02 (d, 1H, J4 Hz, sulfur bridge-H); dC (CDCl3)
10.8 (CH3), 12.0 (CH3), 34.0 (CH2), 50.5 (CH), 51.6 (CH3
ester), 51.7 (CH3 ester), 52.0 (CH), 53.3 (CH), 56.1 (CH),
108.7, 114.4, 132.1, 138.1, 162.9 (CvO ester), 164.7 (CvO
ester), 172.0 (CvO amide) and 173.8 (CvO amide); m/z
M1 378 (33%), 346 (9), 253 (100), 221 (27), 163 (17), 135
(11).
Dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-
6-methyl-2-phenyl-1H-pyrrolo[3,4-f]indolizine-7,8-dicar-
boxylate (6a). Dimethyl 5-methyl-1H,3H-pyrrolo[1,2-c]-
thiazole-6,7-dicarboxylate 2-oxide 5 (0.27 g, 1.0 mmol)
and N-phenylmaleimide gave after recrystallisation from
methanol (exo-adduct) dimethyl 1,3-dioxo-4,9-epithio-
2,3,3a,4,9,9a-hexahydro-6-methyl-2-phenyl-1H-pyrrolo-
[3,4-f]indolizine-7,8-dicarboxylate as a colourless powder,
mp 210±2128C, lit.2 210±2118C. (Found: C, 59.1; H, 4.4; N,
6.5. C21H18N2SO6 requires C, 59.2; H, 4.3 and N, 6.6%);
nmax (Nujolw) 2930, 1714, 1699, 1654, 1595, 1462, 1378,
1308, 1193, 1146, 1093, 919, 843, 785 and 737 cm21; dH
(CDCl3) 2.46 (s, 3H, 5-CH3), 3.48 (d, 1H, J8 Hz, imide
a-H), 3.51 (d, 1H, J8 Hz, imide a-H), 3.83 (s, 3H, ester
CH3), 3.86 (s, 3H, ester CH3), 5.50 (s, 1H, sulfur bridge-H),
6.04 (s, 1H, sulfur bridge-H), 7.26±7.28 and 7.44±7.51 (m,
5H, Ar-H); m/z M1 426 (12%), 392 (10), 360 (11), 274
(37), 253 (100), 221 (33), 163 (23), 135 (14).
Dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-
2,6-dimethyl-1H-pyrrolo[3,4-f]-indolizine-7,8-dicarboxy-
late (7a, exo) and (7b, endo). Dimethyl 5-methyl-1H,3H-
pyrrolo[1,2-c]thiazole-6,7-dicarboxylate 2-oxide 5 (0.27 g,
1.0 mmol), N-methylmaleimide (0.13 g, 1.2 equiv., 1.2
mmol) gave after chromatography [ethyl acetate±hexane
(1:1)] and crystallisation from chloroform±ethanol (exo-
adduct) dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexa-
hydro-2,6-dimethyl-1H-pyrrolo[3,4-f]indolizine-7,8-dicar-
boxylate (0.21 g, 59%) as a colourless powder, mp 190±
1928C. (Found: C, 52.8; H, 4.4; N, 7.7. C16H16N2SO6
requires C, 52.7; H, 4.4 and N, 7.7%); nmax (Nujolw)
2926, 1726, 1699, 1462, 1377, 1307, 1206, 1154 and
1093 cm21; dH (CDCl3) 2.44 (s, 3H, 5-CH3), 3.03 (s, 3H,
N±CH3), 3.33 (d, 1H, J8 Hz, imide a-H), 3.36 (d, 1H,
J8 Hz, imide a-H), 3.82 (s, 3H, ester CH3), 3.86 (s, 3H,
ester CH3), 5.39 (s, 1H, sulfur bridge-H), and 5.93 (s, 1H,
sulfur bridge-H); dC (CDCl3) 11.3 (CH3), 25.4 (CH2), 50.8
(CH), 51.6 (CH3 ester), 51.8 (CH3 ester), 51.9 (CH), 53.5
(CH), 67.0 (CH), 107.8, 114.3, 131.4, 140.3, 162.8 (CvO
ester), 164.9 (CvO ester), 173.3 (CvO amide) and 174.0
(CvO amide); m/z M1 364 (26%), 332 (22), 253 (100), 221
(37), 163 (28), 135 (23), and (endo-adduct) dimethyl 1,3-
dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-2,6-dimethyl-1H-
pyrrolo-[3,4-f]indolizine-7,8-dicarboxylate (0.03 g, 9%) as
a colourless powder, mp 206±2088C. Found: C, 52.7; H,
4.3; N, 7.7. C16H16N2SO6 requires C, 52.7; H, 4.4 and N,
Dimethyl 1,3-dioxo-2,3-dihydro-6-methyl-2-phenyl-1H-
pyrrolo[3,4-f]indolizine-7,8-dicarboxylate (10). A solu-
tion of sodium methoxide (0.38 mL, 30% wt. soln.,
2.0 equiv., 2.0 mmol) added slowly to a solution of dimethyl
1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-6-methyl-2-
phenyl-1H-pyrrolo[3,4-f]indolizine-7,8-dicarboxylate 6a
(0.43 g, 1.0 mmol) dissolved in anhydrous dichloromethane